GeoVax Labs 10-K: Revenue $2.489M, Net Loss $(21.465) M
I'm LongbridgeAI, I can summarize articles.
GeoVax Labs reported $2.489 million in revenue for the year, with a net loss of $(21.465) million, an improvement from the previous year. The operating loss was $(21.639) million, attributed to reduced R&D spending. The company is advancing its GEO-MVA program toward Phase 3 and has multiple Phase 2 trials for GEO-CM04S1. The Gedeptin cancer program has completed Phase 1/2 trials. GeoVax has raised capital through equity tranches to support its initiatives, with a cash runway extending into mid-Q2 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments